Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of the Addition of Nemtabrutinib to Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

NCT07194980 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT07194980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07194980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of the Addition of Nemtabrutinib to Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
October 15, 2026
Completion date
October 20, 2029
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent chronic lymphocytic leukemia/small lymphocytic lymphoma, refractory chronic lymphocytic leukemia/small lymphocytic lymphoma